UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, DCD.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~the~~Date ~~Securities~~of ~~Exchange~~Report ~~Act~~(Date of ~~1934~~earliest event reported): May 15, 2025

Date of report (Date of earliest event reported): March 27, 2025

Lantern Pharma Inc.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Its~~its ~~Charter~~charter)

Delaware		001-39318		46-3973463
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(~~I.R.S.~~IRS Employer Identification ~~Number~~No.)

1920 McKinney Avenue, 7th Floor Dallas, Texas 75201

1920 McKinney Avenue, 7th Floor

Dallas, Texas

75201

(Address of Principal Executive Offices)

(Zip Code)

(Address of principal executive offices)

(972) 277-1136

(Registrant’s telephone number, including area code)

~~(Former~~Check the ~~name~~appropriate orbox ~~former~~below ~~address,~~ if ~~changed~~the ~~since~~Form ~~last~~8-K ~~report~~filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

~~Check~~ ☐ Written communications pursuant to Rule 425 under the ~~appropriate~~Securities ~~box~~Act ~~below~~(17 ifCFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the ~~Form~~Exchange 8Act (17 CFR 240.14a-K12) ~~filing~~☐ isPre-commencement ~~intended~~communications pursuant to ~~simultaneously~~Rule ~~satisfy~~14d-2(b) under the ~~filing~~Exchange ~~obligations~~Act of(17 ~~the~~CFR ~~registrant~~240.14d-2(b)) ~~under any~~☐ ofPre-commencement communications pursuant to Rule 13e-4(c) under the ~~following~~Exchange ~~provisions~~Act (17 CFR 240.13e-4(c))

~~☐ Written communications pursuant to Rule 425 under the~~ Securities registered ~~Act (17 CFR 230.425) ☐ Soliciting material~~ pursuant to ~~Rule~~Section ~~14a-~~12 ~~under the Exchange Act~~ (~~17 CFR 240.14d-2(~~b) ☐of ~~Pre-commencement communications pursuant to Rule 14d-2(b) under~~ the ~~Exchange~~ Act: ~~(17~~Common ~~CFR 240.14d-2(b) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)~~Stock

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value		LTRN		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Securities registered pursuant to Section 12(b)of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock: Par value $.001		LTRN		Nasdaq Capital Market

Item 2.02 Results of Operations and Financial Condition.

On ~~March~~May 2715, 2025, Lantern Pharma Inc. (the “Company”) ~~issued~~will issue a press release announcing its financial results for the ~~fiscal~~first ~~year and fourth~~ quarter ended ~~December~~March 31, ~~2024~~2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On ~~March~~May 2715, 2025, the Company ~~utilized~~will utilize a presentation to assist with the Company’s discussions during a conference call and live webinar hosted by the Company to discuss financial and operating results for the ~~fiscal~~first ~~year and fourth~~ quarter ended ~~December~~March 31, ~~2024~~2025. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits ~~Method Filing~~.

The following exhibits are furnished with this report:

Exhibit No.		Exhibit Description

99.1		Press Release dated May 15, 2025 announcing financial results for quarter ended March 31, 2025.
99.2		Presentation relating to May 15, 2025 conference call and live webinar to discuss financial and operating results for quarter ended March 31, 2025.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Exhibit 99.1	Press Release dated March 27, 2025 announcing financial results for the fiscal year and quarter ended December 31, 2024.	Filed Electronically herewith
Exhibit 99.2	Presentation relating to March 27, 2025 conference call and live webinar to discuss financial and operating results for fiscal year and quarter ended December 31, 2024.	Filed Electronically herewith
Exhibit 104	Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LANTERN PHARMA INC.
	Lantern Pharma Inc.,
Dated: March 27, 2025	/s/ David Margrave
	A Delaware Corporation
	David Margrave,
Dated: May 15, 2025	By:	/s/ David R. Margrave
	Chief Financial Officer
		David R. Margrave, Chief Financial Officer

Filing Compare · Lantern Pharma Inc.